炎症性疾病的生物治疗后的皮肤恶性瘤:一个活跃的比较器,回顾性队列研究
Kyle C Lauck1, Areeba Ahmed2, Michael J Davis3
1Division of Dermatology, Department of Medicine, Baylor University Medical Center, Dallas, Texas.
Journal of the American Academy of Dermatology
|May 23, 2025
概括
生物疗法,特别是瘤亡因子抑制剂,与炎症性疾病患者的非黑色素瘤皮肤癌风险略有增加有关. 仔细选择患者至关重要.
科学领域:
- 皮肤病学 皮肤病学
- 类风湿病学 类风湿病学
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
背景情况:
- 在患有炎症性疾病 (ID) 的患者中,生物疗法与皮肤癌风险之间的关联仍然不清楚.
- 患有ID的患者具有固有的皮肤癌风险较高,独立于治疗.
- 有限的纵向数据存在,在评估生物安全时充分控制与ID相关的混因素.
研究的目的:
- 为了评估在炎症性疾病的生物疗法后发展皮肤恶性瘤的风险.
- 进行不同生物制剂的对比比较,以减轻与潜在炎症疾病相关的混风险.
主要方法:
- 来自TriNetX网络 (2004-2024) 的大型数据集 (1759200名患者) 的分析,包括患有牛皮,类风湿性关节炎和炎症性肠病的患者.
- 在接触各种生物疗法后,计算皮肤恶性瘤风险.
- 适用倾向性得分匹配对潜在混变量进行控制.
主要成果:
- 大约12.1%的患者 (212,632) 为他们的炎症状况接受了生物疗法.
- 观察到非黑色素瘤皮肤癌绝对风险的统计学上显著增加,虽然很小,主要与瘤亡因子 (TNF) 抑制剂有关.
- 对于其他研究的单个生物制剂,没有发现皮肤癌风险的显著增加.
结论:
- 这项研究证实了TNF抑制剂与非黑色素瘤皮肤癌风险增加之间的联系.
- 虽然其他生物制剂,如介质素和简氏激酶抑制剂可能会带来最小的风险,但研究结果强调在管理炎症疾病时需要个性化生物选择.
- 限制包括研究的追溯性质和电子医疗记录固有的潜在数据不准确性.
更多相关视频
04:12Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
14.2K
09:08Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
5.4K
相关概念视频
Skin Cancer
4.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
